Rumor Control Policies for Listed Biotech Firms

Introduction

Rumor control policies are corporate-governance procedures through which a listed company monitors, verifies, and responds to market rumors that may influence investors or the price of its securities. For biotechnology companies, rumors may concern clinical-trial results, vaccine approvals, drug discoveries, regulatory investigations, mergers, licensing deals, product recalls, or manufacturing failures.

A rumor may be false, incomplete, premature, or based on confidential information. Improper responses can mislead investors, create market volatility, and expose the company and its officers to regulatory liability.

In India, rumor verification is governed principally by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), particularly Regulation 30(11), along with applicable SEBI circulars and industry standards.

Securities and Exchange Board of India+1

Core Requirements of a Rumor Control Policy

Under Regulation 30(11) of the LODR Regulations, the top 100 listed entities by market capitalization must verify qualifying market rumors from 1 June 2024, and the next 150 (top 250 in total) from 1 December 2024. The obligation is triggered by material price movement and applies to specific, non-general rumors reported in mainstream media.

msei.in+1

A compliant policy for a listed biotech firm should provide:

Monitoring: Track mainstream media and market reports concerning clinical trials, regulatory approvals, product recalls, acquisitions, and other material events.

Verification: Route the rumor to the company secretary, compliance officer, legal team, and relevant scientific or clinical leadership.

Accurate response: Confirm, deny, or clarify the report and state the current stage of the event. Avoid speculative statements or selective disclosure.

Timely exchange filing: Make the required disclosure to stock exchanges within the prescribed timeline.

Confidentiality: Protect unpublished price-sensitive information (UPSI) and prevent unauthorized employee or insider communications.

Documentation: Preserve the source of the rumor, internal verification records, approvals, and the exact disclosure issued.

The SEBI-backed Industry Standards Note provides operational guidance, including how to assess rumor specificity, material price movement, and transaction-stage disclosures.

ficci.in+1

Relevant Case Laws

1. Reliance Industries Ltd. v. SEBI, Supreme Court, 2 May 2025

The dispute concerned disclosure obligations relating to a market rumor and unpublished price-sensitive information. The judgment addressed the distinction between the earlier discretionary regime and the later mandatory rumor-verification requirement introduced through amendments to Regulation 30(11). It demonstrates that the applicable legal obligation must be determined according to the rule in force at the relevant time.

Indian Kanoon+1

2. N. Narayanan v. Adjudicating Officer, SEBI, (2013) 12 SCC 152

The Supreme Court emphasized that disclosure and transparency are essential to market integrity. Directors and officers must exercise due care and diligence and cannot permit misleading financial disclosures that distort investor decisions. The principle is relevant to biotech firms because misleading statements about clinical results, approvals, or product performance may influence securities trading.

VoxJuris

3. SEBI v. Rakhi Trading Pvt. Ltd., (2018) 13 SCC 753

The Supreme Court stressed that fairness, integrity, and transparency are essential features of the securities market. It recognized that manipulative or non-genuine trading may violate securities regulations where supported by evidence. This principle reinforces the need for listed companies to avoid misleading rumor responses or conduct that contributes to artificial market activity.

Securities and Exchange Board of India+1

Conclusion

Rumor control policies are important for protecting investors and maintaining market integrity in listed biotechnology firms. A compliant policy should combine monitoring, rapid internal verification, accurate disclosure, confidentiality, and documented decision-making. Regulation 30(11) and SEBI’s industry standards establish specific rumor-verification obligations for qualifying listed entities, while judicial decisions emphasize transparency, fair dealing, and evidence-based enforcement.

There is no single biotech-specific judicial rule governing all rumors. The general securities-law framework applies, with particular importance attached to the accuracy of statements about clinical trials, regulatory approvals, product safety, and commercial transactions.